Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexrazoxane Hydrochloride

FDA-approved product (injectable, injection), marketed as Dexrazoxane Hydrochloride, Totect, Zinecard.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Dexrazoxane Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Cardiomyopathy
  • Extravasation of Diagnostic and Therapeutic Materials

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Dexrazoxane Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA25.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexrazoxane Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexrazoxane Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • High-Risk Neuroblastoma Chemotherapy Without G-CSF

    NCT02786719 · start 2016-06

    Registered record
    Registry ID
    NCT02786719
    Conditions
    Neuroblastoma
    Interventions
    Topotecan; Cyclophosphamide; Cisplatin; Etoposide; Vincristine; Cyclophosphamide; Doxorubicin; Sargramostim
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-06
    Completion
    2019-02-05
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    InterventionTopotecan; Cyclophosphamide; Cisplatin; Etoposide +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation

    NCT02519335 · start 2014-09

    Registered record
    Registry ID
    NCT02519335
    Conditions
    Heart Defects, Congenital
    Interventions
    Dexrazoxane
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2014-09
    Completion
    2017-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Defects, Congenital
    InterventionDexrazoxane
    PhasePhase 1
    Registry statusTerminated

  • Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

    NCT01790152 · start 2014-03-05

    Registered record
    Registry ID
    NCT01790152
    Conditions
    Hodgkin Lymphoma in Remission; Leukemia in Remission; Lymphoblastic Lymphoma; Osteosarcoma; Recurrent Leukemia; Recurrent Lymphoma; Recurrent Malignant Neoplasm
    Interventions
    Assessment of Therapy Complications; Laboratory Biomarker Analysis; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2014-03-05
    Completion
    2026-12-31
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma in Remission; Leukemia in Remission; Lymphoblastic Lymphoma; Osteosarcoma +3 more
    InterventionAssessment of Therapy Complications; Laboratory Biomarker Analysis; Quality-of-Life Assessment; Questionnaire Administration
    PhaseNot recorded
    Registry statusRecruiting

  • Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

    NCT01864109 · start 2013-05

    Registered record
    Registry ID
    NCT01864109
    Conditions
    Newly Diagnosed Ewing Sarcoma
    Interventions
    Cyclophosphamide; Doxorubicin; Vincristine; Ifosfamide; Etoposide; Surgery; Radiation Therapy*; Temozolomide; Irinotecan; Mesna; Dexrazoxane; G-CSF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-05
    Completion
    2027-05
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNewly Diagnosed Ewing Sarcoma
    InterventionCyclophosphamide; Doxorubicin; Vincristine; Ifosfamide +8 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    NCT01606878 · start 2013-04-29

    Registered record
    Registry ID
    NCT01606878
    Conditions
    Childhood Solid Neoplasm; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Neuroblastoma
    Interventions
    Crizotinib; Cyclophosphamide; Dexrazoxane Hydrochloride; Doxorubicin Hydrochloride; Laboratory Biomarker Analysis; Pharmacological Study; Questionnaire Administration; Topotecan Hydrochloride; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-04-29
    Completion
    2018-12-31
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Solid Neoplasm; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Neuroblastoma
    InterventionCrizotinib; Cyclophosphamide; Dexrazoxane Hydrochloride; Doxorubicin Hydrochloride +5 more
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination

    NCT01627938 · start 2012-04

    Registered record
    Registry ID
    NCT01627938
    Conditions
    Multiple Sclerosis
    Interventions
    Dexrazoxane (DRZ) plus Mitoxantrone (MX); Placebo plus Mitoxantrone (MX)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2012-04
    Completion
    2016-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionDexrazoxane (DRZ) plus Mitoxantrone (MX); Placebo plus Mitoxantrone (MX)
    PhasePhase 2
    Registry statusUnknown

  • Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

    NCT01523977 · start 2011-11

    Registered record
    Registry ID
    NCT01523977
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    Everolimus; Prednisone; Vincristine; PEG-Asparaginase; Doxorubicin; Dexrazoxane
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11
    Completion
    2018-11
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    InterventionEverolimus; Prednisone; Vincristine; PEG-Asparaginase +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

    NCT01258634 · start 2010-07

    Registered record
    Registry ID
    NCT01258634
    Conditions
    Osteosarcoma; Lung Metastases
    Interventions
    Dexrazoxane; Doxorubicin; Cisplatin; G-CSF; PEG-filgrastim; Etoposide; Ifosfamide; Mesna; Leucovorin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2010-07
    Completion
    2011-11
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteosarcoma; Lung Metastases
    InterventionDexrazoxane; Doxorubicin; Cisplatin; G-CSF +5 more
    PhasePhase 1
    Registry statusTerminated

  • Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults

    NCT01696669 · start 2010-03-30

    Registered record
    Registry ID
    NCT01696669
    Conditions
    Ewing's Sarcoma
    Interventions
    Chemotherapy; Surgery; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03-30
    Completion
    2018-01-18
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEwing's Sarcoma
    InterventionChemotherapy; Surgery; Radiotherapy
    PhasePhase 2
    Registry statusCompleted

  • Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

    NCT00980460 · start 2009-09-15

    Registered record
    Registry ID
    NCT00980460
    Conditions
    PRETEXT I Hepatoblastoma; PRETEXT II Hepatoblastoma; PRETEXT III Hepatoblastoma; PRETEXT IV Hepatoblastoma
    Interventions
    Cisplatin; Dexrazoxane; Doxorubicin Hydrochloride; Fluorouracil; Irinotecan Hydrochloride; Laboratory Biomarker Analysis; Liver Transplantation; Temsirolimus; Therapeutic Conventional Surgery; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09-15
    Completion
    2026-03-31
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPRETEXT I Hepatoblastoma; PRETEXT II Hepatoblastoma; PRETEXT III Hepatoblastoma; PRETEXT IV Hepatoblastoma
    InterventionCisplatin; Dexrazoxane; Doxorubicin Hydrochloride; Fluorouracil +6 more
    PhasePhase 3
    Registry statusCompleted

  • Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

    NCT00933985 · start 2009-06

    Registered record
    Registry ID
    NCT00933985
    Conditions
    Acute Leukemias of Ambiguous Lineage; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refrac
    Interventions
    dexrazoxane hydrochloride; doxorubicin hydrochloride; obatoclax mesylate; liposomal vincristine sulfate; pharmacological study; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-06
    Completion
    2013-04
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Leukemias of Ambiguous Lineage; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia +21 more
    Interventiondexrazoxane hydrochloride; doxorubicin hydrochloride; obatoclax mesylate; liposomal vincristine sulfate +2 more
    PhasePhase 1
    Registry statusTerminated

  • Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer

    NCT00955890 · start 2009-06

    Registered record
    Registry ID
    NCT00955890
    Conditions
    Breast Cancer
    Interventions
    Dexrazoxane hydrochloride; Dexrazoxane hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-06
    Completion
    2012-02
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDexrazoxane hydrochloride; Dexrazoxane hydrochloride
    PhasePhase 2
    Registry statusTerminated

  • Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

    NCT00928200 · start 2009-04-13

    Registered record
    Registry ID
    NCT00928200
    Conditions
    Relapsed Acute Lymphoblastic Leukemia; Allergy to PEG e.Coli Asparaginase; Allergy to Native e.Coli Asparaginase
    Interventions
    Erwinase; Vincristine; Dexamethasone; Doxorubicin; Cytarabine; Methotrexate; Triple Intrathecal Therapy; Dexrazoxane
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-04-13
    Completion
    2010-06-04
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Acute Lymphoblastic Leukemia; Allergy to PEG e.Coli Asparaginase; Allergy to Native e.Coli Asparaginase
    InterventionErwinase; Vincristine; Dexamethasone; Doxorubicin +4 more
    PhasePhase 1
    Registry statusTerminated

  • Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

    NCT00742924 · start 2008-08

    Registered record
    Registry ID
    NCT00742924
    Conditions
    Sarcoma
    Interventions
    cisplatin; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide; ifosfamide; leucovorin calcium; methotrexate; zoledronic acid; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery; filgrastim; Mesna
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventioncisplatin; dexrazoxane hydrochloride; doxorubicin hydrochloride; etoposide +9 more
    PhasePhase 1
    Registry statusCompleted

  • Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

    NCT00673179 · start 2008-05

    Registered record
    Registry ID
    NCT00673179
    Conditions
    Osteosarcoma
    Interventions
    Doxorubicin; Cisplatin; Methotrexate; Leucovorin; Dexrazoxane; Ifosfamide; Questionnaire; Gemcitabine; Sargramostim; Surgery; Mesna
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2008-05
    Completion
    2010-11
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteosarcoma
    InterventionDoxorubicin; Cisplatin; Methotrexate; Leucovorin +7 more
    PhaseNot applicable
    Registry statusTerminated